Marimed Inc. (MRMD) Stock Price & Analysis
Marimed Inc. (MRMD) rose 0.00% to USD 0.07 as of July 25, 2026 at 05:14 UTC, according to Nexqual real-time market data.
MRMD last closed at USD 0.07; the session ranged USD 0.06–0.07 on volume of 7,100 shares. Market capitalization is $26.35M, with a 52-week range of USD 0.06–0.23 (OQB). Source: Nexqual, July 25, 2026 at 05:14 UTC.
Key Statistics (as of July 25, 2026 at 05:14 UTC)
| Price | USD 0.07 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.07 |
| Open | USD 0.06 |
| Day Range | USD 0.06 – 0.07 |
| 52-Week Range | USD 0.06 – 0.23 |
| Volume | 7,100 shares |
| Market Cap | $26.35M |
| Exchange | OQB |
Technical Analysis (MRMD)
Nexqual's technical model rates MRMD "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 05:14 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 41.19 (neutral) |
| vs SMA50 | Below (USD 0.07) |
| MACD | -0 (negative) |
Analyst Ratings (MRMD)
Wall Street analysts rate MRMD "Strong Buy", per Nexqual as of July 25, 2026 at 05:14 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (MRMD)
| Next Earnings Date | 2026-08-12 |
|---|---|
| Revenue Estimate | $39.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.01 vs est -0.01 ▲ beat |
| 2025-12-31 | USD 0.01 vs est -0.01 ▲ beat |
| 2025-09-30 | USD -0 vs est -0.01 ▲ beat |
| 2025-06-30 | USD 0 vs est -0.01 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:14 UTC.
Financials & Fundamentals (MRMD)
| Total Revenue | $161.40M |
|---|---|
| Revenue Growth (YoY) | +4.20% |
| Gross Margin | +35.98% |
| Operating Margin | +0.74% |
| Profit Margin | -7.91% |
| ROE | -20.01% |
| Debt / Equity | 170.66 |
| Current Ratio | 0.95 |
| Total Cash | $7.94M |
| Total Debt | $91.21M |
| Free Cash Flow | $15.18M |
Source: Nexqual, July 25, 2026 at 05:14 UTC.
Financial Health Score (MRMD)
Nexqual rates Marimed Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 05:14 UTC.
| Growth | Mixed — Revenue +1.2% YoY (annual), slow |
|---|---|
| Profitability | Mixed — Gross margin 36%, operating 1% |
| Balance Sheet | Critical — $8M cash vs $91M debt |
| Cash Flow | Solid — FCF $15M, 9% margin |
| Efficiency | Critical — ROE -20%, ROA -0.4% |
Ownership (MRMD)
| Insider Ownership | +14.67% |
|---|---|
| Institutional Ownership | +0.24% |
| Shares Outstanding | 399.27M |
| Float | 331.83M |
Source: Nexqual, July 25, 2026 at 05:14 UTC.
Leadership (MRMD)
Marimed Inc. is led by Jon R. Levine (age 60), Co-Founder, CEO, President, Secretary, Treasurer & Director, per Nexqual as of July 25, 2026 at 05:14 UTC.
| Co-Founder, CEO, President, Secretary, Treasurer & Director | Jon R. Levine (age 60) |
|---|---|
| Chief Operating Officer | Timothy Shaw (age 46) |
| Chief Financial Officer | Mario Pinho (age 57) |
| Vice President of Human Resources | Marlo Richard |
| Retail Director of Mid-Atlantic | Alexander Swartz |
Major Backers & Investors (MRMD)
Notable institutional backers of Marimed Inc. include AdvisorShares Trust-AdvisorShares Pure US Cannabis ETF, Canton Hathaway, LLC, according to Nexqual as of July 25, 2026 at 05:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AdvisorShares Trust-AdvisorShares Pure US Cannabis ETF | 0.96% |
| Canton Hathaway, LLC | 0.16% |
Source: Nexqual, July 25, 2026 at 05:14 UTC.
From Marimed Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Competitive Strengths We believe that our strengths in the following areas provide us with certain competitive advantages and the tools necessary to successfully implement our strategic plans: Portfolio of Proprietary and Innovative Brands We have developed a portfolio of unique and market-leading brands which are currently distributed in cannabis-legal states.
- We have created and continue to develop our own brands of premium cannabis flower, concentrates, edibles, and other precision-dosed products utilizing our proprietary strains and formulations.
- We also license our proprietary brands, in select domestic markets, although licensing revenues are not material to our overall results of operations.
- Wholesale Operations We operate state-of-the-art, regulatory-compliant cannabis cultivation and processing facilities that grow and manufacture our proprietary, high quality, branded cannabis consumer products.
Partnerships
- We also entered into a license agreement with a client in 2025 that will enable the distribution of our products in that state following regulatory approvals.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CVSI | CV Sciences, Inc. | USD 0.02 | ▲ 0% |
| ITHUF | iAnthus Capital Holdings, Inc. | USD 0 | ▲ 0% |
| CBWTF | Auxly Cannabis Group Inc. | USD 0.13 | ▲ 1.54% |
| CWBHF | Charlotte's Web Holdings Inc. | USD 0.24 | ▲ 8.11% |
| GTBIF | Green Thumb Industries Inc. | USD 7.02 | ▼ 0.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:14 UTC. This page is informational and not investment advice.